Startseite » Publications

Publications i-Target

Original Papers

 

Doctoral students of i-Target are marked in blueproject leaders in black, associated doctoral students (otherwise funded) in light blue.

 

2021

 

58. Ecker V, Stumpf M, Brandmeier L, Neumayer T, Pfeuffer L, Engleitner T, Ringshausen I, Nelson N, Jücker M, Wanninger S, Zenz T, Wendtner C, Manske K, Steiger K, Rad R, Müschen M, Ruland J, Buchner M.
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia.
Nature Communications 2021; 12:3526
JIF 12.1

 

57. Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S.
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.
Science Advances 2021;7:eabi5781
JIF 13.1

 

56. Brand I, Gilberg L, Bruger J, Garí M, Wieser A, Eser TM, Frese J, Ahmed MIM, Rubio-Acero R, Guggenbuehl Noller JM, Castelletti N, Diekmannshemke J, Thiesbrummel S, Huynh D, Winter S, Kroidl I, Fuchs C, Hoelscher M, Roider J, Kobold S, Pritsch M, Geldmacher C.
Broad T cell targeting of structural proteins after SARS-CoV-2 infection: High throughput assessment of T cell reactivity using an automated interferon gamma release assay.
Frontiers in Immunology 2021; 12:688436.
JIF 5.1

 

55. Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadieu E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S.
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Nature Biomedical Engineering 2021; doi: 10.1038/
JIF 19

 

54. Frey L, Ziętara N, Łyszkiewicz M, Marquardt B, Mizoguchi Y, Linder MI, Liu Y, Giesert F, Wurst W, Dahlhoff M, Schneider MR, Wolf E, Somech R, Klein C.
Mammalian VPS45 orchestrates trafficking through the endosomal system.
Blood 2021; 137:1932-1944.
JIF 17.5

 

53. Rohrbacher L, Brauchle B, Ogrinc Wagner A, von Bergwelt-Baildon M, Bücklein VL, Subklewe M.
The PI3K∂-selective inhibitor idelalisib induces T- and NK-cell dysfunction independently of B-cell malignancy-associated immunosuppression.
Frontiers in Immunology 2021; 12: 608625.
JIF 5.1

 

52. Alankus B, Ecker V, Vahl N, Braun M, Weichert W, Macher-Göppinger S, Gehring T, Neumayer T, Zenz T, Buchner M, Ruland J.
Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia.
Journal of Experimental Medicine 2021; 218: e20200517
JIF 11.7

 

51. Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S.
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Leukemia 2021; 7:1–15. 
JIF 9.9

 

2020

 

50. Schmitt S, Tahk S, Lohner A, Hänel G, Maiser A, Hauke M, Patel L, Rothe M, Josenhans C, Leonhardt H, Griffioen M, Deiser K, Fenn NC, Hopfner KP and Subklewe M.
Fusion of bacterial flagellin to a dendritic cell-targeting αCD40 antibody construct coupled with viral or leukemia-specific antigens enhances dendritic cell maturation and activates peptide-responsive T cells.
Frontiers in Immunology,2020; in press
JIF 5.1

49. Brix N, Samaga D, Hennel R, Gehr K, Zitzelsberger H, Lauber K.
The clonogenic assay: robustness of plating efficiency-based analysis is strongly compromised by cellular cooperation. 
Radiation Oncology
2020; 15:248.
JIF 2.8

 

48. Ernst A, Hennel R, Krombach J, Kapfhammer H, Brix N, Zuchtriegel G, Uhl B, Reichel CA, Frey B, Gaipl US, Winssinger N, Shirasawa S, Sasazuki T, Sperandio M, Belka C, Lauber K
Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90.
Frontiers in Oncology 2020; 10:1668. 
JIF 4.7

  

47. Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T.
CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy.
Blood 2020; in press
JIF 10.7

 

46. Piseddu I, Röhrle N, Knott MML, Moder S, Eiber S, Schnell K, Vetter V, Meyer B, Layritz P, Kühnemuth B, Wiedemann GM, Gruen J, Perleberg C, Rapp M, Endres S, Anz D.
Constitutive Expression of CCL22 is mediated by T cell-derived GM-CSF.
The Journal of Immunology 2020; 205:2056-2065.
JIF 4.3

 

45. Boehmer D, Koehler L, Magg T, Metzger P, Rohlfs M, Ahlfeld J, Rack-Hoch A, Reiter K, Albert M, Endres S, Rothenfusser S, Klein Ch, Koenig L, Hauck F.
A novel complete autosomal recessive STAT1 LOF variant causes immunodeficiency with hemophagocytic lymphohistiocytosis-like hyperinflammation.
The Journal of Allergy and Clinical Immunology 2020; 8:3102-3111
JIF 10.3

 

44. Geiger M, Stubenrauch KG, Sam J, Richter W, Jordan G, Eckmann J, Hage C, Gonzalez-Nicolini V, Freimoser-Grundschober A, Ritter M, Lauer M, Stahlberg H, Ringler P, Patel J, Sullivan E, Grau-Richards S, Endres SKobold S, Umaña P, Brünker P, Klein Ch.
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Nature Communications 2020; 24:3196
JIF 12.3

 

43. Metzger PKirchleitner S, Boehmer D, Hörth Ch, Eisele A, Ormanns S, Gunzer M, Lech M, Lauber KEndres S, Duewell P, Schnurr MKönig L.
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Cancer Immunology Immunotherapy 2020; 69:2101-2112
JIF 4.9

 

42. Stenger D, Stief T, Kaeuferle T, Willier S, Rataj F, Schober K, Binje V, Lotfi R, Wagner B, Grünewald T, Kobold S, Busch D, Jeremias I, Blaeschka F, Feuchtinger T.
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Blood 2020; 17:1407-1418
JIF 10.7

 

41. Park E, Chen J, Moore A, Mangolini M, Santoro A, Boyd JR, Schjerven H, Ecker V, Buchner M, Williamson JC, Lehner PJ, Gasparoli L, Williams O, Bloehdorn J, Stilgenbauer S, Leitges M, Egle A, Schmidt-Supprian M, Frietze S, Ringshausen I.
Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance.
Science Translational Medicine 2020; 12:526
JIF 8.3

 

40. Tohumeken S, Baur R, Böttcher M, Stoll A, Loschinski R, Panagiotidis K, Braun M, Saul D, Völkl S, Baur AS, Bruns H, Mackensen A, Jitschin R, Mougiakakos D.
Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2/Akt/mTOR signaling.
Cancer Research 2020; 80:3663-3676
JIF 9.7

 

39. Łyszkiewicz M, Ziętara N, Frey L, Pannicke U, Stern M, Liu Y, Fan Y, Puchałka J, Hollizeck S, Somekh I, Rohlfs M, Yilmaz T, Ünal E, Karakukcu M, Patiroğlu T, Kellerer C, Karasu E, Sykora KW, Lev A, Simon A, Somech R, Roesler J, Hoenig M, Keppler OT, Schwarz K, Klein C.
Human FCHO1 deficiency reveals role for clathrin-mediated endocytosis in development and function of T cells.
Nature Communications 2020; 11:1031.
JIF 12.3

 

2019

38. Sustmann C, Dickopf S, Regula JT, Kettenberger H, Mølhøj M, Gassner C, Weininger D, Fenn S, Manigold T, Kling L, Künkele KP, Schwaiger M, Bossenmaier B, Griese JJ, Hopfner KP, Graff-Meyer A, Stahlberg H, Ringler P, Lauer ME, Brinkmann U, Schaefer W, Klein C.
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
MAbs. 2019;11:1402-1414.
JIF 4.4

 

37. Helms M, Jahn-Hofmann K, Gnerlich F, Metz-Weidmann,C, Braun M, Dietert G, Scherer P, Grandien K, Theilhaber J, Cao H, Wagenaar T, Schnurr M, Endres S, Wiederschain D, Scheidler S, Rothenfusser S, Brunner B, König LM. 
Utility of the RIG-I agonist triphosphate RNA for melanoma therapy. 
Molecular Cancer Therapeutics 2019; 18:2343-2356.
JIF 4.9

 

36. Mountford SA, Ringleb A, Schwaiger R, Mayr D, Kobold S, Dinarello Ch, Bufler P.
Interleukin-37 inhibits colon carcinogenesis during chronic colitis.
Frontiers in Immunology 2019; 10:2632.
JIF 4.7

 

35. Darowski D, Jost Ch, Stubenrauch K, Wessels U, Benz J, Ehler A, Freimoser-Grundschober A, Brünker P, Mössner E, Umana P, Kobold S, Klein Ch.
P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.
Protein Engineering, Design and Selection 2019; 32:207-218
JIF 2.0

 

34. Lorenz G, Moschovaki-Filippidou F, Würf V, Metzger P, Steiger S, Batz F, Carbajo-Lozoya J, Koziel J, Schnurr M, Cohen C, Schmaderer C, Anders H, Lindenmeyer M, Lech M.
IFN regulatory factor 4 controls post-ischemic inflammation and prevents chronic kidney disease.
Frontiers in Immunology 2019; 10:2162

JIF 4.7

 

33. Metzger P, Kirchleitner S, Kluge M, Koenig L, Hoerth Ch, Rambuscheck CA, Boehmer D, Ahlfeld J, Kobold S, Friedel C, Endres S, Schnurr M, Duewell P.
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.
Journal for Immunotherapy of Cancer 2019; 7:288
JIF 8.7

 

32. Ruzicka M*, König L*, Formisano S, Boehmer D, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhoefler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger F*, Rothenfusser S*.
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Leukemia 2019; 34:1017-1026
JIF 9.9
* contributed equally to this study

 

31. Wiedemann G, Röhrle N, Makeschin MC, Fesseler J, Endres S, Mayer D, Anz D.
Peritumoral CCL1 and CCL2 expressing cells in hepatocellular carcinomas shape the tumor immune infiltrate.
Pathology 2019; 51:586-592
JIF 3.2

 

30. Karches C*, Benmebarek MR*, Schmidbauer M, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha B, Lesch S, Heise C, Murr R, vom Berg J, Jastroch M, Lamp D, Ding J, Duewell P, Niederfellner G, Sustmann C, Endres S, Klein Ch, Kobold S.
Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy.
Clinical Cancer Research 2019; 25:5890-5900
JIF 8.9
* contributed equally to this study

 

29. Rapp M, Wintergerst M, Kunz W, Vetter VKnott M, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer BRöhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian U, Endres S, Anz D.
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
Journal of Experimental Medicine 2019; 116:5514-5522.
JIF 10.9

 

28. Liu X, Li J, Cadilha B, Markota A, Voigt C, Huang Z, Lin P, Wang D, Juncheng D, Kranz G, Krandick A, Libl D, Zitzelsberger H, Zagorski I, Braselmann H, Pan M, Zhu S, Huang Y, Niedermeyer S, Reichel Ch, Uhl B, Briukhovetska D, Suarez Gosalvez JKobold S, Gires O, Wang H.
Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis.
Science Advances 2019; 5:eaav4275.
JIF11.5  

 

27. Rataj F, Jacobi SStoiber SAsang F, Ogonek J, Tokarew N, Cadilha B, van Puijenbroek E, Heise C, Düwell PEndres S, Klein Ch, Kobold S.
High affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
British Journal of Cancer 2019; 120:79-87
JIF 6.2

 

26. Wiedemann G, Aithal CKraechan A, Heise C, Cadilha B, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold S.
Microphthalmia-associated transcription factor (MITF) regulates immune cell migration into melanoma.
Translational Oncology 201912:350-360.
JIF 3.1

 

2018

25. Jitschin R, Saul D, Braun M, Tohumeken S, Völkl S, Kischel R, Lutteropp M, Dos Santos C, Mackensen A, Mougiakakos D.
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Journal for Immuno Therapy of Cancer 2018: 6:116

24. Keppler SJ, Burbage M, Gasparrini F, Hartjes L, Aggarwal S, Massaad MJ, Geha RS, Bruckbauer A, Batista FD.
The lack of WIP binding to actin results in impaired B cell migration and altered humoral immune responses.
Cell Reports 2018; 24:619-629

23. Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Blood 2018; 132:2484-2494

22. Rataj F, Kraus F, Chaloupka M, Grassmann S, Heise C, Cadilha B, Duewell P, Endres S, Kobold S.
PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin-lymphoma.
Frontiers in Immunology 2018; 9:1955
JIF 6.4

21. Weidenbusch M, Song S, Iwakura T, Shi C, Rodler S, Kobold S, Mulay SR, Honarpisheh MM, Anders HJ.
IL-22 sustains epithelial integrity in progressive kidney remodeling and fibrosis.
Physiological Reports 2018; 6:e13817

20. Andrade L, Tay R, Pan D, Luoma A, Ito Y, Badrinath S, Tsoucas D, Franz B, May K, Harvey Ch, Kobold S, Pyrdol J, Yoon Ch, Yuan G, Hodi S, Dranoff G, Wucherpfennig K.
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity.
Science 2018359:1537-1542.
JIF 35.3


19. Damby D, Horwell C, Baxter P, Kueppers U, Schnurr M, Dingwell D, Duewell P.
Volcanic ash activates the NLRP3 inflammasome in murine and human macrophages.
Frontiers in Immunology 2018; 8:2000
JIF 6.4


18. Metzger PKirchleitner S, König L, Hörth Ch, Kobold SEndres SSchnurr MDuewell P.
Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.
Science Reports 2018; 8
JIF 4.8

 

17. Makanyengo RDuewell P, Reichl C, Hörth Ch, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold SEndres SSchnurr M, Bauer Ch.
Nlrp3-dependent IL-1ß inhibits CD103+ dendritic cell differentiation in the gut.
Journal of Clinical Investigation 2018;
JIF 6,0

 

16. Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schlüter M, Neitz J, Subklewe M.
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
Frontiers in Immunology 2018; 9:385.
JIF 5.5

 

15. Loschinski R, Böttcher M, Stoll A, Bruns H, Mackensen A, Mougiakakos D.
IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner.
Oncotarget 2018; 9(17): 13125-13138

 

2017

 

14. Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT,  Arendt KAM, Heise C, Rataj F, Janssen KP, Königshofff M, Winter H, Himsl I, Thasler WE, Schnurr M, Rothenfußer S, Endres S and Kobold S.
Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.
Proceedings of the National Academy of Sciences USA 2017; 114(49):12994-12999
JIF 9.6
* contributed equally to this study

  

13. Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.
Using antigen-specific B cells to combine antibody and T cell-based cancer immunotherapy.
Cancer Immunology Research 2017; 5(9):730-743
JIF 8.2

 

12. Cadilha B, Dormann K, Rataj F, Endres S and Kobold S.
Enabling T cell recruitment to tumours as a strategy for improving adoptive T cell therapy. 
European Oncology and Hematology 2017; 13:66-73

 

11. Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe MHopfner KP.
SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Oncotarget 2017; 8(7):11284-11301
JIF 5.0
 

 

2016

 

10. Groß CJ, Mishra R, Schneider KS, Médard G, Wettmarshausen J, Dittlein DC, Shi H, Gorka O, König PA, Fromm S, Magnani G, Ćiković T, Hartjes L, Smollich J, Robertson AAB, Cooper MA, Schmidt-Supprian M, Schuster M, Schroder K, Broz P, Traidl-Hoffmann C, Beutler B, Kuster B, Ruland J, Schneider S, Perocchi F, Groß O.
K+ efflux-independent NLRP3 inflammasome activation by a small molecule targeting mitochondria.
Immunity 2016; 45:1-13.
JIF 24.1

 

9. Qorraj M, Bruns H, Böttcher M, Weigand L, Saul D, Mackensen A, Jitschin R, Mougiakakos D.
The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
Leukemia 2016; doi:10.1038/leu.2016.214.
JIF 12.1

 

8. Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S.
C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.
Oncoimmunology 2016; 5:e1105428.
JIF 7.3

 

7. Roskopf C, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, Oduncu FS.
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.
Oncotarget 2016; 7:22579-22589.
JIF 5.0

 

6. Wiedemann G, Jacobi SChaloupka M, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell PEndres SKobold S.
A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.
Oncoimmunology 2016; 5:e1189051.
JIF 7.3

 

5. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf C, Wildenhain S, Honegger A, Schubert IA, Schele A, Lämmermann K, Fey GH, Jacob U, Lang P, Hopfner KP, Oduncu FS.
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B lymphoid cells.
Oncotarget; 7:83392-83408.
JIF 5.0

 

2015

 

4. Kobold S, Steffen J, Chaloupka MGrassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.
Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
The Journal of the National Cancer Institute 2015; 107:364.
JIF 15.2

 

3. Kobold S*, Grassmann S*, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, Endres S#, Rothenfußer S#.
Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy.
The Journal of the National Cancer Institute 2015; 107: djv146.
JIF 15.2

* contributed equally to this study, # share senior authorship

 

2. Ernst A, Anders H, Kapfhammer H, Orth M, Hennel R, Seidl K, Winssinger N, Belka C, Unkel S, Lauber K.
HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas.
Cancer Letters 2015; 365:211-222.
JIF 5.0

 

1. Duewell P, Beller E, Kirchleitner S, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold SEndres SSchnurr M.
Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.
Oncoimmunology 2015; 4: e1029698.
JIF 6.3

 

B Reviews

2021 

 

17. Schwerdtfeger M, Benmebarek MR, Endres S, Subklewe M, Desiderio V, Kobold S.
Chimeric antigen receptor-modified T cells and T cell-engaging bispecific antibodies: Different tools for the same Job.
Current Hematologic Malignancy Report 2021;16: 218-233.
JIF 2.5

2020

 

16. Vornholz L, Ruland J
Physiological and Pathological Functions of CARD9 Signaling in the Innate Immune System. 
Current Topics Microbiology and Immunology 2020; 429: 177-203 

 

2019

 

15. Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.
Advances in cancer immunotherapy 2019 - latest trends.
Journal of Expimental and Clinical Cancer Research 2019; 38:268.

 

14. Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S.

Determinants of response and resistance to CAR T cell therapy.
Seminars in Cancer Biology 2019, 6: S1044-579

  

13. Stoiber S, Cadilha B, Benmebarek MR, Lesch S, Endres S, Kobold S.
Limitations in the design of chimeric antigen receptors for cancer therapy.
Cells 2019; 8:E472:1-26

  

12. Benmebarek MR, Karches C, Cadilha B, Lesch S, Endres S, Kobold S.
Killing mechanisms of chimeric antigen receptor (CAR) T cells.
International Journal of Molecular Sciences 2019; 20(6)

  

11. Hartjes L, Ruland J.
CARD9 Signaling in Intestinal Immune Homeostasis and Oncogenesis.
Frontiers in Immunology 2019; 11 

  

10. Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K.
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Radiation Oncology 2019 14:1 - 20

  

9. Ruland J, Hartjes L.
CARD-BCL-10-MALT1 signalling in protective and pathological immunity.
Nature Reviews Immunology 2019; 2:118-134

 

2017

 

8. Cadilha B, Dorman K, Rataj F, Endres S, Kobold S.
Enabling T cell recruitment to tumors as a strategy for improving adoptive T cell therapy.
European Oncology and Haematology 2017; 13:66-73.

  

7. Brix N, Tiefenthaller AAnders HBelka C, Lauber K.
Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences.
Immunological Reviews 2017; 280:249-279


2016

 

6. Bauer C, Kühnemuth B, Düwell P, Ormanns S, Gress T, Schnurr M.
Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Cancer Letters 2016; 381:259-268.
JIF 6.0

 

2015

 

5. Weidenbusch M, Rodler S, Anders HJ.
Interleukin-22 in kidney injury and regeneration.
American Journal of Physiology - Renal Physiologogy 2015; 308:F041-1046.
JIF 3.2

 

4. Lauber K, Brix N, Ernst A, Hennel R, Krombach J, Anders H, Belka C.
Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.
Cancer Letters 2015; 15:162-167.
JIF 5.0 

 

3. Schnurr MDüwell P, Bauer C, Rothenfusser S, Lauber KEndres SKobold S.
Strategies to relieve immunosuppression in pancreatic cancer.
Immunotherapy 2015; 7:363-376.
JIF 2.4

 

2. Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.
Immunotherapy of tumors – Activated T cells as a new treatment modality.
Deutsches Ärzteblatt International 2015; 112:809-15.
JIF 3.7

 

2014

 

1. Kobold S, Wiedemann G, Rothenfusser S, Endres S.
Modes of action of TLR7 agonists in cancer therapy.
Immunotherapy 2014; 6:1085-95.
JIF 2.4